Multiple Binding Sites Contribute to the Mechanism of Mixed Agonistic and Positive Allosteric Modulators of the Cannabinoid CB1 Receptor.

The cannabinoid CB1 receptor (CB1R) is an abundant metabotropic G-protein-coupled receptor that has been difficult to address therapeutically because of CNS side effects exerted by orthosteric drug candidates. Recent efforts have focused on developing allosteric modulators that target CB1R. Compounds from the recently discovered class of mixed agonistic and positive allosteric modulators (Ago-PAMs) based on 2-phenylindoles have shown promising functional and binding properties as CB1R ligands. Here, we identify binding modes of both the CP 55,940 agonist and GAT228, a 2-phenylindole allosteric modulator, by using our metadynamics simulation protocol, and quantify their affinity and cooperativity by atomistic simulations. We demonstrate the involvement of multiple adjunct binding sites in the Ago-PAM characteristics of the 2-phenylindole modulators and explain their ability to compete with orthosteric agonists at higher concentrations. We validate these results experimentally by showing the contribution of multiple sites on the allosteric binding of ZCZ011, another homologous member of the class, together with the orthosteric agonist.

[1]  Alexandros Makriyannis,et al.  Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome , 2008, Physiology & Behavior.

[2]  S. Goldberg,et al.  Self-administration of Δ9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys , 2003, Psychopharmacology.

[3]  M. Haney,et al.  Actions of delta-9-tetrahydrocannabinol in cannabis: Relation to use, abuse, dependence , 2009, International review of psychiatry.

[4]  S. P. Andrews,et al.  Extra-helical binding site of a glucagon receptor antagonist , 2016, Nature.

[5]  Timothy Clark,et al.  An Efficient Metadynamics-Based Protocol To Model the Binding Affinity and the Transition State Ensemble of G-Protein-Coupled Receptor Ligands , 2017, J. Chem. Inf. Model..

[6]  Alexandros Makriyannis,et al.  Latest advances in cannabinoid receptor agonists , 2009, Expert opinion on therapeutic patents.

[7]  J. Wess,et al.  Activation and allosteric modulation of a muscarinic acetylcholine receptor , 2013, Nature.

[8]  Ali Jazayeri,et al.  Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). , 2015, Journal of medicinal chemistry.

[9]  J. Deschamps,et al.  Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor. , 2017, ACS chemical neuroscience.

[10]  K. Mackie,et al.  Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities , 2017, Neuropharmacology.

[11]  Hualiang Jiang,et al.  Structure of the full-length glucagon class B G protein-coupled receptor , 2017, Nature.

[12]  J. P. Grossman,et al.  Biomolecular simulation: a computational microscope for molecular biology. , 2012, Annual review of biophysics.

[13]  R. Pertwee,et al.  Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond , 2008, Addiction biology.

[14]  A. Christopoulos,et al.  Allosteric Modulation of the Cannabinoid CB1 Receptor , 2005, Molecular Pharmacology.

[15]  R. Ross.  Allosterism and cannabinoid CB(1) receptors: the shape of things to come. , 2007, Trends in pharmacological sciences.

[16]  A. Doré,et al.  Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain , 2014, Nature.

[17]  U. Holzgrabe,et al.  The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling , 2012, Nature Communications.

[18]  Jens Meiler,et al.  Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator , 2014, Science.

[19]  Noureldin Saleh,et al.  Identification of Two Distinct Sites for Antagonist and Biased Agonist Binding to the Human Chemokine Receptor CXCR3. , 2016, Angewandte Chemie.

[20]  T. Clark,et al.  Differences between G-Protein-Stabilized Agonist-GPCR Complexes and their Nanobody-Stabilized Equivalents. , 2017, Angewandte Chemie.

[21]  Shan Jiang,et al.  Crystal structures of agonist-bound human cannabinoid receptor CB1 , 2017, Nature.

[22]  A. Lichtman,et al.  A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects , 2015, Neuropsychopharmacology.

[23]  Arthur Christopoulos,et al.  Emerging paradigms in GPCR allostery: implications for drug discovery , 2013, Nature Reviews Drug Discovery.

[24]  V. Marzo.  CB1 receptor antagonism: biological basis for metabolic effects , 2008 .

[25]  R. Pertwee.  Endocannabinoids and Their Pharmacological Actions. , 2015, Handbook of experimental pharmacology.

[26]  S A Deadwyler,et al.  Cannabinoids Reveal the Necessity of Hippocampal Neural Encoding for Short-Term Memory in Rats , 2000, The Journal of Neuroscience.

[27]  V. Marzo,et al.  Targeting the endocannabinoid system: to enhance or reduce? , 2008, Nature Reviews Drug Discovery.

[28]  Jana Sopkova-de Oliveira Santos,et al.  A Three-Site Mechanism for Agonist/Antagonist Selective Binding to Vasopressin Receptors. , 2016 .

[29]  Ruben Abagyan,et al.  Structure of CC Chemokine Receptor 2 with Orthosteric and Allosteric Antagonists , 2016, Nature.

[30]  Pál Pacher,et al.  Modulating the endocannabinoid system in human health and disease – successes and failures , 2013, The FEBS journal.

[31]  D. Janero.  Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists , 2012, Expert opinion on emerging drugs.

[32]  E. Valjent,et al.  Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with Δ‐9‐tetrahydrocannabinol , 1998, British journal of pharmacology.

[33]  Jie Yin,et al.  High-resolution crystal structure of the human CB1 cannabinoid receptor , 2016, Nature.

[34]  Nestor Etxebarria,et al.  Targeting the endocannabinoid system: future therapeutic strategies. , 2016, Drug discovery today.

[35]  Stephen P. H. Alexander,et al.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.

[36]  F. Gervasio,et al.  Investigating allosteric effects on the functional dynamics of β2-adrenergic ternary complexes with enhanced-sampling simulations† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c6sc04647a , 2017, Chemical science.

[37]  P. Sexton,et al.  Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor , 2015, Molecular Pharmacology.

[38]  Hualiang Jiang,et al.  Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex , 2013, Science.

[39]  A. Lichtman,et al.  Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats , 1995, Psychopharmacology.

[40]  Chris de Graaf,et al.  Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators , 2017, Nature.